StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)

Close on Nov 17, 2026Market cap $257.81KP/E –Yield –

Virax Biolabs price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Virax Biolabs's price to book ratio was 0.0× on Nov 11, 2026, against 0.3× a year earlier. Over the last 4 years it ranged from 0.0× to 2.2×, with a median of 0.5×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.0×−0.2
2025Dec 31, 20250.3×−0.8
2024Dec 31, 20241.1×+0.8
2023Dec 29, 20230.2×–

More Virax Biolabs figures

See a number that looks wrong?